Technical Analysis for CLDX - Celldex Therapeutics, Inc.

Grade Last Price % Change Price Change
D 33.64 1.34% 0.45
CLDX closed up 3.3 percent on Friday, June 2, 2023, on 62 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 1.34%
Crossed Above 50 DMA Bullish 1.34%
Gapped Up Strength 1.34%
Up 3 Days in a Row Strength 1.34%
Up 4 Days in a Row Strength 1.34%
Up 5 Days in a Row Strength 1.34%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 4.68%
MACD Bullish Signal Line Cross Bullish 4.68%
Inside Day Range Contraction 4.68%
Up 3 Days in a Row Strength 4.68%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 25 minutes ago
Rose Above Previous Day's High about 3 hours ago
Up 1% about 3 hours ago
50 DMA Support about 3 hours ago
50 DMA Resistance about 4 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Celldex Therapeutics, Inc. Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer. The company also has various earlier stage candidates in clinical development, such as CDX-1135, a molecule that inhibits a part of the immune system called the complement system; CDX-1127, a therapeutic fully human monoclonal antibody for cancer indications that is in Phase I study in patients with selected malignant solid tumors or hematologic cancers; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, which completed Phase I study in healthy subjects; and CDX-1401, an antibody-targeted technology program for cancer indications that completed Phase I study in combination with toll-like receptor agonists poly-ICLC. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Thomas Jefferson University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immunology Solid Tumors Immune System Clinical Development Immunotherapy Cancer Treatment Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Breast Cancer Genetics Ovarian Cancer Treatment Of Breast Cancer Blastoma Glioblastoma Antibody Drug Conjugate Brain Tumor Cancer Center Cancer Research Complement System Pivotal Hematologic Cancers Advanced Breast Cancer Dendritic Cell Targeted Immunotherapy Recurrent Glioblastoma Rockefeller University

Is CLDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 48.4
52 Week Low 19.85
Average Volume 592,188
200-Day Moving Average 36.57
50-Day Moving Average 33.18
20-Day Moving Average 32.61
10-Day Moving Average 32.05
Average True Range 1.40
RSI (14) 52.15
ADX 12.61
+DI 29.15
-DI 26.13
Chandelier Exit (Long, 3 ATRs) 31.54
Chandelier Exit (Short, 3 ATRs) 34.45
Upper Bollinger Bands 34.82
Lower Bollinger Band 30.40
Percent B (%b) 0.63
BandWidth 13.55
MACD Line -0.50
MACD Signal Line -0.63
MACD Histogram 0.1239
Fundamentals Value
Market Cap 1.31 Billion
Num Shares 39.6 Million
EPS -3.74
Price-to-Earnings (P/E) Ratio -8.87
Price-to-Sales 114.73
Price-to-Book 3.74
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.17
Resistance 3 (R3) 34.97 34.11 34.84
Resistance 2 (R2) 34.11 33.61 34.21 34.73
Resistance 1 (R1) 33.65 33.29 33.88 33.85 34.62
Pivot Point 32.79 32.79 32.91 32.89 32.79
Support 1 (S1) 32.33 32.29 32.56 32.53 31.76
Support 2 (S2) 31.47 31.97 31.57 31.65
Support 3 (S3) 31.01 31.47 31.54
Support 4 (S4) 31.21